Own immune cells shrink tumors in advanced melanoma trial
NCT ID NCT01005745
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new way to treat metastatic melanoma by using a patient's own immune cells. Doctors removed a tumor, grew special immune cells (TILs) from it in a lab, then gave them back to the patient along with high-dose IL-2. Before the cell infusion, patients received strong chemotherapy to make room for the new cells. The main goal was to see if this approach was feasible and safe. Nineteen patients took part, and researchers measured whether the cells could grow and whether tumors shrank.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tumor-infiltrating lymphocytes (TIL) plus high-dose interleukin-2 (IL-2)
- What this could lead to
- If successful, this approach could offer a new treatment option for advanced melanoma that has spread, potentially shrinking tumors in some patients.
- What could go wrong
- This was a very small, early-phase trial with only 19 participants. The treatment involves intense chemotherapy and high-dose IL-2, which can cause severe side effects. Not all patients responded.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Two punch of immune boosters revive cancer treatment?
- Could a personal coach at home boost energy for cancer patients?
- Morning vs. afternoon: could the clock boost immunotherapy against melanoma?
- Could a common vaccine supercharge immunotherapy against melanoma?
- Engineered immune cells take aim at Hard-to-Treat cancers
- New drug cocktail targets rare, aggressive melanoma